Fasching, Peter A. http://orcid.org/0000-0003-4885-8471
Hartkopf, Andreas D.
Gass, Paul
Häberle, Lothar
Akpolat-Basci, Leyla
Hein, Alexander
Volz, Bernhard
Taran, Florin-Andrei
Nabieva, Naiba
Pott, Birgit
Overkamp, Friedrich
Einarson, Hanna
Hadji, Peyman
Tesch, Hans
Ettl, Johannes
Lüftner, Diana
Wallwiener, Markus
Müller, Volkmar
Janni, Wolfgang
Fehm, Tanja N.
Schneeweiss, Andreas
Untch, Michael
Pott, Dirk
Lux, Michael P.
Geyer, Thomas
Liedtke, Cornelia
Seeger, Harald
Wetzig, Sarah
Hartmann, Arndt
Schulz-Wendtland, Rüdiger
Belleville, Erik
Wallwiener, Diethelm
Beckmann, Matthias W.
Brucker, Sara Y.
Kolberg, Hans-Christian
Funding for this research was provided by:
Celgene
Pfizer
Novartis Pharma
Article History
Received: 3 October 2018
Accepted: 10 October 2018
First Online: 15 October 2018
Compliance with ethical standards
:
: P.G. has received honoraria from Novartis and financial support for symposia from Novartis, Roche, and PharmaMar. A.D.H. has received honoraria from Teva, GenomicHealth, Celgene, AstraZeneca, Novartis, Pfizer, and Roche. F.A.T. has received honoraria from AstraZeneca, GenomicHealth, Novartis, and Roche. N.N. has received consultancy honoraria from Janssen-Cilag and travel support from Novartis. F.O. has received speaker and consultancy honoraria from Amgen, Celgene, AstraZeneca, Novartis, Roche, and MSD. P.H. has received honoraria, unrestricted educational grants, and research funding from Amgen, AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, and Roche. H.T. has received honoraria from Novartis, Roche, Celgene, TEVA, and Pfizer, and travel support from Roche, Celgene, and Pfizer. J.E. has received honoraria from Roche, Celgene, Novartis, Pfizer, Pierre Fabre, and TEVA, and travel support from Celgene, Pfizer, TEVA, and Pierre Fabre. D.L. has received honoraria from Aurikamed, Roche, Pfizer, Novartis, Celgene, AstraZeneca, Eli Lilly, and L’Oreal. M.W. has received speaker honoraria from AstraZeneca, Celgene, and Novartis. V.M. has received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Pierre-Fabre, Novartis, Roche, Teva, and Janssen-Cilag, and consultancy honoraria from Genomic Health, Roche, Pierre Fabre, Amgen, Daiichi-Sankyo, and Eisai. W.J. has received honoraria and research grants from Novartis. A.S. has received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH, and promedicis GmbH. M.P.L. has received honoraria from Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, TEVA, Celgene, Eisai, medac, and Thieme for advisory boards, lectures, and travel support. C.L. reports personal fees from Celgene, from TEVA, from Pierre Fabre, from Novartis, from Amgen, from Eisai, from GSK, from Roche, from Puma, from Hexal, from Daiichi Sankyo, and from Genomic Health, outside of the submitted research. E.B. received honoraria from Novartis for consulting and clinical research management activities. P.A.F. has received honoraria from Roche, Pfizer, Novartis, and Celgene. His institution conducts research for Novartis. H.-C.K. has received honoraria from Carl Zeiss meditec, TEVA, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, and Genomic Health. All of the remaining authors have declared no conflicts of interest.
: All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.